Co-Diagnostics, Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Co-Diagnostics, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2020 to 2023.
  • Co-Diagnostics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was -$2.21M, a 62.9% decline year-over-year.
  • Co-Diagnostics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$2.42M, a 49.7% increase from 2022.
  • Co-Diagnostics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$4.81M, a 617% decline from 2021.
  • Co-Diagnostics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $930K.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$2.42M +$2.39M +49.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 -$4.81M -$5.74M -617% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $930K +$1.48M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$547K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.